DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Table 25–8
Vasopressin Receptor Agonists
I. NATURALLY OCCURRING VASOPRESSIN-LIKE PEPTIDES
A. Vertebrates A W X Y Z
1. Mammals
Arginine vasopressin a (AVP) (humans NH 2
Tyr Phe Gln Arg
and other mammals)
Lypressin a (pigs, marsupials) NH 2
Tyr Phe Gln Lys
Phenypressin (macropodids) NH 2
Phe Phe Gln Arg
2. Nonmammalian vertebrates
Vasotocin NH 2
Tyr Ile Gln Arg
B. Invertebrates
1. Arginine conopressin (Conus striatus) NH 2
Ile Ile Arg Arg
2. Lysine conopressin (Conus geographicus) NH 2
Phe Ile Arg Lys
3. Locust subesophageal ganglia peptide NH 2
Leu Ile Thr Arg
II. SYNTHETIC VASOPRESSIN PEPTIDES
A. V 1
-selective agonists
1. V 1a
-selective: [Phe 2 , Ile 3 , Orn 8 ] AVP NH 2
Phe Ile Gln Orn
2. V 1b
-selective: Deamino H D-3-(3′-pyridyl)-Ala 2 Phe Gln Arg
[D-3-(3′-pyridyl)-Ala 2 ]AVP
B. V 2
-selective agonists
1. Desmopressin a (DDAVP) H Tyr Phe Gln D-Arg
2. Deamino[Val 4 , D-Arg 8 ]AVP H Tyr Phe Val D-Arg
III. NONPEPTIDE AGONIST
A. OPC-51803
N
H
N
Cl
O
N
O
a
Available for clinical use.
smooth muscle cells in the uterus, causing milk ejection
and uterine contraction, respectively. Inasmuch as
vasopressin and oxytocin are structurally similar, it is
not surprising that vasopressin and oxytocin agonists
and antagonists can bind to each other’s receptors.
Therefore, most of the available peptide vasopressin
agonists and antagonists have some affinity for oxytocin
receptors; at high doses, they may block or mimic the
effects of oxytocin.
Many vasopressin analogs were synthesized with the goal of
increasing duration of action and selectivity for vasopressin receptor
subtypes (V 1
versus V 2
vasopressin receptors, which mediate
pressor responses and antidiuretic responses, respectively).
Deamination at position 1 increases duration of action and increases